Trans N-Methyl-N-[2-(1-pyrrolidinyl)cyclohexyl] cycloprop-2-ene-1-carboxamides: Novel lipophilic kappa opioid agonists

Bioorganic and Medicinal Chemistry Letters

Volumn 7, Issue 3, 1997, Pages 291-296

  Sabin, V ^a,c   Horwell, D C ^a   McKnight, A T ^a   Broqua, P ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b Institut de Recherche Jouveinal   (France)

^c Chiroscience Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 DICHLORO N METHYL N [2 (1 PYRROLIDINYL)CYCLOHEXYL]BENZENEACETAMIDE; ENADOLINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; OPIATE AGONIST;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; IN VITRO STUDY; LIPOPHILICITY; MOUSE; NONHUMAN; RABBIT; RAT; SEDATION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; VAS DEFERENS; VASOCONSTRICTION;

EID: 0031552091     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(96)00615-4     Document Type: Article

References (19)

1. 1. Von Voigtlander, P. F.; Lahti, R. A.; Ludens, J. H. J. Pharmacol. Exp. Ther., 1983, 224, 7.
2. 2. Halfpenny, P. R.; Horwell, D. C.; Hughes, J.; Hunter, J. C.; Rees, D. C. J. Med. Chem., 1990, 33, 286.
3. 3. Barber, A.; Gottschlich, R. Med. Res. Rev., 1992, 12, 525.
4. 4. Hansch, C.; Bjorkroth, J. P.; Leo, A. J. Pharm. Sci., 1987, 76, 663 and references therein.
5. 5. Shaw, J. S.; Carroll, J. A.; Alcock, P.; Main, B. G. Br. J. Pharmacol., 1989, 96, 986.
6. 6. Gottschlich, R.; Ackermann, K. A.; Barber, A.; Bartoszyk, G. D.; Greiner, H. E. Bioorg. Med. Chem. Lett., 1994, 4, 677.
7. 7. Compounds were evaluated for their ability to inhibit the contractions af electrically stimualted rabbit vas deferens. The procedure was based on that of Oka, T.; Negishi, K.; Suda, M.; Matsumiya, T.; Inazu, T.; Ueki, M. Eur. J. Pharmacol., 1980, 73, 235.
8. 8. Clark, C. R.; Halfpenny, P. R.; Hill, R. G.; Horwell, D. C.; Hughes, J.; Jarvis, T. C.; Rees, D. C.; Schofield, D. J. Med. Chem., 1988, 31, 831.
9. 9. All new compounds gave satisfactory spectroscopic and analytical data.
10. 10. Smith, L. I.; Howard, K. L. Org. Synth. Coll. Vol. 3, 351.
11. 11. Prepared according to the procedure of Hermann, W. A. Chem. Ber., 1979, 1731.
12. 12. Diphenylacetylene was commercially available. 2(3 and 4-chlorophenyl)phenylacetylene were prepared following the procedure of Stevens, D.; Castro, C. E. J. Org. Chem., 1963, 28, 3313. 2(3-acetoxyphenyl)phenylacetylene was prepared following the procedure of Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron Lett., 1975, 4467.
13. 12. Diphenylacetylene was commercially available. 2(3 and 4-chlorophenyl)phenylacetylene were prepared following the procedure of Stevens, D.; Castro, C. E. J. Org. Chem., 1963, 28, 3313. 2(3-acetoxyphenyl)phenylacetylene was prepared following the procedure of Sonogashira, K.; Tohda, Y.; Hagihara, N. Tetrahedron Lett., 1975, 4467.
14. 13. Kaplan, L. J. US Patent 4,438,130, March 20, 1984; Chem Abstr., 1984, 101, 54912w.
15. 13. Kaplan, L. J. US Patent 4,438,130, March 20, 1984; Chem Abstr., 1984, 101, 54912w.
16. 14. The Log P and interpolated Log D values were determined at Sirius Analytical Instruments, East Sussex, UK.
17. 3H]-U-69593 in cloned rat kappa opioid receptor, expressed in CHO cell line.
18. 3H]-DAGO in rat brain mu opioid receptor.
19. 17. Leighton, G. E.; Johnson, M. A.; Meecham, K. G.; Hill, R. G.; Hughes, J. Br. J. Pharmacol., 1987, 92, 915.